Meeting
2022 ASCO Annual Meeting
First-in-human clinical trial of an oncolytic adenovirus armed with TNFa and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.
Authors
Inge Marie Svane
National Center for Cancer Immune Therapy, CCIT-DK, Copenhagen University Hospital, Herlev, Denmark
Inge Marie Svane , Victor Cervera-Carrascon , Joao Manuel Santos , Riikka Havunen , Suvi Sorsa , Marco Donia , Amir Khammari , Brigitte Dréno , Akseli Hemminki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04217473
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9590)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9590
Abstract #
TPS9590
Poster Bd #
182b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2015 ASCO Annual Meeting
A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma.
First Author: Joseph Clark
Poster
2022 ASCO Annual Meeting
A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies.
First Author: Eugenia Girda